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A bstract
Background: Paratonia, a form of hypertonia, is associated with loss of mobility and with the 
development of contractures especially in the late stages of the dementia.
Passive movement therapy (PMT) currently is the main physiotherapeutic intervention. General doubt 
about the beneficial effects of this widely used therapy necessitates a randomised clinical trial (RCT) to 
study the efficacy of PMT on the severity of paratonia and on the improvement of daily care.
Methods/Design: A RCT with a 4-week follow-up period. Patients with dementia (according to the 
DSM-IV-TR Criteria) and moderate to severe paratonia are included in the study after proxy consent. By 
means of computerised and concealed block randomisation (block-size of 4) patients are included in one 
of two groups. The first group receives PMT, the second group receives usual care without PMT. PMT is 
given according to a protocol by physical therapist three times a week for four weeks in a row. The 
severity of paratonia (Modified Ashworth scale), the severity of the dementia (Global Deterioration Scale), 
the clinical improvement (Clinical Global Impressions), the difficulty in daily care (Patient Specific 
Complaints) and the experienced pain in daily care of the participant (PACSLAC-D) is assessed by 
assessors blind to treatment allocation at baseline, after 6 and 12 treatments.
Success of the intervention is defined as a significant increase of decline on the modified Ashworth scale. 
The 'proportion of change' in two and four weeks time on this scale will be analysed. Also a multiple logistic 
regression analysis using declined/not declined criteria as dependent variable with correction for relevant 
confounders (e.g. stage of dementia, medication, co-morbidity) will be used.
Discussion: This study is the first RCT of this size to gain further insight on the effect of passive 
movement therapy on the severity of paratonia.
Trial registration: Current Controlled Trials ISRCTN43069940
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Background
Paratonia is one of the m otor problems seen in persons 
with dementia and was first described by Dupré in 1910 
as the inability to relax muscles in combination with a 
mental disorder [1]. Paratonia is hypothesized to develop 
centrally bu t to exert an effect on peripheral biomechan­
ics. Especially in the late stages of dementia it is associated 
with loss of mobility and with the development of con­
tractures [2-5]. Thus, paratonie has a negative impact on 
the quality of life and can result in problems with washing 
and dressing
The prevalence of paratonia ranges from 5% in the early 
stages of dementia to 100% in the advanced stages [2,5]. 
We found an estimated prevalence of paratonia of approx­
imately 80% in a group of Dutch nursing home patients 
with dementia [6]. Passive movement therapy (PMT) is a 
therapeutic intervention designed to increase the passive 
extensibility of muscles, ligaments and collagen in order 
to achieve maximal joint range of m otion [7,8]. A recent 
NIVEL report revealed that PMT is with 28.2% one of the 
main physiotherapeutic interventions in Dutch nursing 
homes, with an average duration of 30 minutes per 
patient per week [9]. This therapy is generally believed to 
be effective in patients with paratonia [10,11]. Profes­
sional workers claim that this therapy, if given shortly 
before washing and bathing, facilitates the care for the 
patients, due to improved range of m otion of affected 
limbs. Investigations in other populations, e.g., patients 
with spasticity and contractures show a temporal effect or 
a so-called elastic deformation due to the visco-elastic 
properties in all tissues [7]. However, after 20 to 30 m in­
utes, joint range of m otion returns to the starting values. 
Plastic deformation, or a permanent effect, is only possi­
ble if the patient can actively use the gained mobility[7,8]. 
Furthermore, animal studies indicate that when activated 
muscles fibres are stretched, which is the case with PMT in 
paratonia, older tissues are more susceptible to injury on 
sarcomere level [12]. Given the fact that these frail 
patients, who often show signs of discomfort during the 
treatment, are prone to injury and are not able to actively 
use regained mobility PMT is controversial. Nonetheless, 
maybe because of a lack of alternatives, or because of pres­
sure of concerned relatives, physicians and physiothera­
pist start PMT. A pilot study in 15 patients with paratonia 
confirmed that PMT had positive short term effects, but 
trend analyses of long term effects showed that after 3 
weeks hypertonia increased slightly in 30% in the PMT 
group in comparison with 10% in the control groups, 
indicating a possible association with muscle fibre inju­
ries [3]. We feel this is a relevant finding, however, the 
small sample size of this pilot study, and the lack of a clear 
operational definition of paratonia did not allow for firm 
conclusions concerning the efficacy of PMT.
Before designing a new trial with sufficient power we 
therefore initiated a Delphi procedure with known experts 
in the field to achieve a new consensus definition of para- 
tonia. After four Delphi-rounds, the experts agreed on 7 
criteria for operational defining paratonia (see below) 
[13]. Consequently these criteria have been assessed on 
validity and reliability in a 3-phase cross-sectional study 
in which this definition was tailored even further and in 
which we developed an assessment instrument (the Para- 
tonia Assessment Instrument, PAI) for an instant diagno­
sis of paratonia, thus providing researchers an operational 
tool for future trials on paratonia [6].
"Paratonia is a form of hypertonia with an involuntary variable 
resistance during passive movement. The nature of paratonia 
may change with progression of the dementing illness (e.g. 
active assistance (Mitgehen) is more common early in the 
course of degenerative dementias, whilst active resistance is 
more common later in the course of the disease). The degree of 
resistance varies depending on the speed of movement (e.g. a 
low resistance to slow movement and a high resistance to fast 
movement). Paratonia increases with progression of dementia. 
Furthermore, the resistance to passive movement is in any 
direction and there is no clasp-knife phenomenon." The resist­
ance must be felt in either two directions in one limb or in two 
different limbs.
We designed a randomized clinical trial in order to answer 
three research questions; first, is passive movement ther­
apy an effective intervention on the severity of paratonia 
in comparison with usual care without passive movement 
therapy?
Second, is passive movement therapy an effective inter­
vention for improvement of daily care? And finally, does 
PMT reduce pain during daily care in patients with m od­
erate to severe paratonia.
Methods
To answer these 3 research questions we use a randomised 
clinical trial with 4 weeks of follow-up.
Patients
The study population consists of patients with dementia 
(according to the DSM-IV-TR Criteria) and established 
paratonia according to the Paratonia Assessment Instru­
m ent (PAI). The PAI is a construct of five criteria derived 
from the definition, representing distinct elements of the 
clinical manifestation of paratonia [6]. The resistance felt 
during passive movement due to paratonia has to be at 
least in one of the limbs more marked i.e. a score of 2 or 
more on the modified Ashworth scale. Possible partici­
pants will be identified by trained personnel of participat­
ing nursing homes. After identification of participants the 
researcher checks if the patient is eligible for the study and
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if so will contact the legal representative(s) of the patient 
by sending an information leaflet about the study. 
Patients are only included after proxy consent. Because 
patients are included after proxy consent we will exclude 
participants who indicate during the trial in any way, ver­
bally or nonverbally, not to approve of participation. 
Patients with an unstable disease, as judged by the nursing 
home physician, such as progressive malignant cancer or 
other diseases with an obvious progressive negative effect 
on the m otor function or health status are excluded as 
well as patients who received passive movement therapy 
within a period of 4 weeks prior to admission or who 
receive typical or a-typical antipsychotics.
Interventions
Patients are included in one of two groups after computer­
ised and concealed block randomisation (block size of 
four). The first group receives usual care with PMT, the 
second group receives usual care without PMT. Usual care 
generally consists of grooming and dressing with slow and 
gentle movements by trained nurses. Some of the partici­
pants wear especially designed clothing that enables the 
nurses to dress patients more easy while the patient is 
lying in bed or sitting in a wheelchair. Most participants 
use cushions, mostly manufactured on demand, for a sta­
ble position in bed and sit during the day time in comfort­
able wheelchairs.
PMT is provided in a standardized way. During the first 
part of passive movement the therapist moves slowly the 
affected limbs, with the emphasis on lowering the resist­
ance. After this, the therapist tries to reach the end range 
of m otion and possibly stretches the structures very lightly 
without causing pain. The patients are positioned com­
fortably supine in bed while the therapist starts PMT with 
the left arm moving it in flexion and extension (up and 
down). Subsequently PMT is performed on the right arm, 
left leg and finally the right leg. The duration of PMT is 
approximately 20 minutes per patient per session. The 
treatment group receives PMT, between 8 a.m. and 10 
a.m., shortly before being washed and dressed by nursing 
staff, three times a week for four weeks in a row. In order 
to safeguard blinding of the assessors for treatment alloca­
tion, the control group receives a placebo treatment in the 
same frequency and in the same time frame. The patients 
of the control group are positioned comfortably supine in 
bed after which the therapist stays in the room for approx­
imately 20 minutes. On every treatment day a special sign­
board on the participant's bedroom door indicates that 
research is going on advising nursing staff to delay their 
activities with the participant and not disturb the treat­
m ent session.
Outcome measures
The Modified Ashworth scale is the primary outcome 
measure and tested with an acceptable reliability to assess 
the severity of paratonia (intrarater reliability; Kendall's 
Tb 0.62-0.80 and interrater reliability; Kendall's Tb 0.72­
0.77) [14]. It is a 5 point scale ranging from 0 to 4, in 
which 0 = no resistance to passive movement, 1 = slight 
resistance during passive movement, 2 = more marked 
resistance to passive movement, 3 = considerable resist­
ance to passive movement, 4 = severe resistance, passive 
movement is impossible. Severity of paratonia will be 
assessed by assessors blinded to treatment allocation at 
baseline one day prior to treatment start, one day after 
treatment 6 (after 2 weeks) and one day after treatment 12 
(after 4 weeks) between 8 a.m. and 10 a.m. before wash­
ing and dressing by nursing staff.
To assess the severity of paratonia all four limbs will be 
passively moved in flexion and extension with the partic­
ipant in a comfortable position supine in bed.
As secondary outcome measures we assess The Pain 
Assessment Checklist for Seniors with Limited Ability to 
Communicate (PACSLAC-D) [15,16], to assess a decrease 
of pain as a possible side effect of PMT The PACSLAC-D is 
an observational assessment instrument that lists 24 items 
divided in three categories; nonverbal facial signs (10 
items), total resistance (6 items) and emotional state (8 
items). This version, a reduction of the original 60 item 
PACSLAC scale had high levels of internal consistency for 
the complete scale (Cronbach's alpha range 0.82-0.86) 
and for all subscales (alpha range 0.72-0.82) [17].
An independent observer will assess the PACSLAC-D in 
both groups by a 5-minute observation of washing and 
dressing within an hour after the first, sixth and the 
twelfth treatment session. Another secondary outcome 
measure is the Clinical Global Impressions scale (CGI) to 
assess clinical change. With this CGI, especially appointed 
nurses, who are blinded for treatment allocation, compare 
the participant with all other patients with paratonia on 
their ward on a 7 point scale from normal to m ost severe 
and rate after 2 and 4 weeks the global improvement also 
on a 7 point scale from very much improved to very much 
worse. Finally, the modified "Patient Specific Complaint" 
(PSC) assessment is used, in which the nurses are asked to 
address the 3 most difficult items in daily care and rate 
these items on a visual analogue scale of 100 mm, with at 
the extreme ends "no trouble at all" and "impossible". The 
frequencies of all assessments are illustrated in Table 1.
At baseline we will register demographic information and 
relevant variables such as age, sex, use of medication, type 
of dementia and severity of the dementia. Severity of 
dementia is assessed with the Global Deterioration Scale
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Table 1: Assessm ent schedule
Assessm ent scale (Assessed by) T0 T1 T2
Modified A sh w o rth  (Assessor, 
blind for treatm ent allocation) 
P A C S L A C  (independent asses­
sor, b lind for treatm ent a lloca­
tion)
C G I and P S C  (Nurse, b lind for  
treatm ent allocation)
G D S  (N urse)
One day prior to treatment start 
on the day of the first treatment
One day prior to treatment start 
Within a week before trial start
One day after treatment 6 
On the day of the sixth treatment
One day after treatment 6
One day after treatment 12 
On the day of the twelfth treatment
One day after treatment 12
which consists of seven stages of cognitive decline in 
which stage 1 = no cognitive decline, level 2 = very mild 
cognitive decline, level 3 = mild cognitive decline, level 4 
= moderate cognitive decline, level 5 = moderately severe, 
level 6 = severe and level 7 = very severe cognitive decline 
[18]. Psychoactive medications will be classified using the 
Anatomical Therapeutical Chemical-classification and 
grouped into antipsychotics, anxiolytics, hypnotics/seda­
tives, antidepressants, anti-epileptics and miscellaneous 
(e.g. cholinesterase inhibitors) [19].
Sample size
The Modified Ashworth Scale is our primary outcome 
measure. A trend analysis of the pilot study data showed a 
worsening of paratonia in 30% of the group with PMT 
and in 10%, possibly due to natural course, of the group 
with usual care without PMT [3]. We consider this effect as 
clinical important. With an alpha of 0.05 and a power of 
80% a sample size of 69 patients per group (taking into 
account a drop-out percentage of 10%) is needed to detect 
this effect.
Analysis
All data will be analysed with SPSS 15.0. The Modified 
Ashworth scale, an ordinal 5-point scale, will be measured 
at 3 times, at baseline (T0) after 2 weeks (T1) and after 4 
weeks (T2). Our premise in this study is that PMT causes 
an accelerated worsening of paratonia over 4 weeks time. 
Success of the intervention is defined as a significant (p <
0.05) difference between the proportion of change on the 
modified Ashworth scale in the two groups.
To determine any development or change over time of 
The Modified Ashworth score in the two groups the Stu­
art-Maxwell statistic will be used.
The difference in proportion of change between the two 
groups will be calculated and tested for significance [20]. 
However controlling for relevant confounders e.g. age, 
sex, severity and type of dementia is not possible with this 
analysis. Therefore a multiple logistic regression analysis 
will be performed on the dichotomised outcome meas­
ure, "declined" and "stable/improved", of the difference 
on T0 and T2 on The Modified Ashworth score.
Missing data will be assumed to be missing at random. 
The Last Observation Carried Forward m ethod will be 
used in those cases with no last measurement (T2) yet 
with valid data from the second assessment (T1). Analyses 
will be carried out according to the intention to treat prin­
ciple.
Study timeline
The estimated project time is 18 months. The project will 
start with an extensive training of relevant staff of all par­
ticipating nursing homes. The training period will take 
two months. After this training the inclusion period will 
start and will run for twelve months. Analysis of data and 
writing of the report is estimated to take 4 months.
The study has been approved by the local ethical commit­
tee CMO nr. 2006/1567, ABR file nr. NL13777.091.06.
The investigator will notify the accredited local ethical 
committee of the end of the study within a period of 8 
weeks. The end of the study is defined as the last patient's 
last follow-up measurement. Within one year after the 
end of the study the investigator will submit a final study 
report with the results, including any publication/ 
abstracts of the study to the accredited local ethical com­
mittee. The investigators are not restricted in any way to 
publish the results of the study.
Discussion
This study is the first RCT of this size to gain further 
insight on the effect of passive movement therapy on the 
severity of paratonia.
Ethical aspects
PMT is a very common physiotherapeutic intervention in 
patients with moderate to severe paratonia. Although it is 
controversial and possibly harmful for these frail elderly, 
in lack of evidence based alternative interventions, most 
therapists perform PMT. For this reason we designed this
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RCT in a very pragmatic way, close to daily practice 
bounded by ethical aspects limiting the time frame of 4 
weeks per participant and using assessment tools that are 
valid and reliable bu t above all with a minimal burden for 
the frail participants. Although we realise that further 
assessments after the end of the treatment period could 
have given more insight in the duration of the effect of 
PMT, the frailty of the participants prevails over the aims 
of research. For the same reason we decided to use no 
invasive methods, such as muscle biopsy to assess possi­
ble tissue damage.
Bias
With the use of the consensus definition a homogeneous 
population should be guaranteed although research in the 
more severe cases of paratonia indicates that if the resist­
ance in affected limbs is very high the assessor is no t able 
to accelerate the movement and adequate differentiation 
with Parkinsonian (lead pipe) rigidity becomes impossi­
ble [6]. Furthermore, we did not specify the type of 
dementia in the inclusion criteria. At this m om ent we 
know that in the advanced stages of the disease all patients 
have paratonia. However, it is unclear if there are any dis­
similarities in the development and severity of paratonia 
in different types of dementia. Therefore paratonia, diag­
nosed in different dementias, could react inconsistently to 
PMT and although we take this into account in our analy­
sis this uncertainty could be a potential source of bias.
With this study, we hope to clarify the effect of passive 
movement therapy on moderate to severe paratonia and 
hopefully gain some scientific basis for the use of this 
treatment or to abandon PMT in this population. The con­
troversy between the hypothesis of the research team that 
PMT is possibly harmful and the assumption of nurses 
and relatives that it is beneficial, necessitates a thorough 
organisation for keeping all assessors blind for treatment 
allocation. Therefore randomisation is done in a block 
size randomisation system with block size of four. For 
each participating nursing hom e a new sequence is calcu­
lated at the faculty of Epidemiology of the Maastricht Uni­
versity. The blinding of the assessors can be compromised 
by an incidental verbal h in t of one of the participants 
although most of the participants are in the advanced 
stage of dementia and lost there capacity of speech.
validity
The research will be conducted in four different nursing 
homes, that will enhance extrapolation of study findings. 
However, due to the fact that at least 4 different geriatric 
physical therapists will perform PMT and at least two dif­
ferent assessors of the severity of paratonia will partici­
pate, the internal validity may become compromised. A 
protocollized way of performing PMT and an extensive 
training of all therapists and assessors involved should
ensure internal validity of this study and reliability of 
assessed outcomes.
The results of this randomised controlled trial will be pub­
lished in a scientific journal and will be used for recom­
mendations in the guideline of geriatric physical therapy 
and implemented in current physical therapy practice. 
This guideline will be developed according to method of 
clinical practice guideline development of the Royal 
Dutch Physiotherapy Association (KNGF) [21].
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